Ahn H, Jung WJ, Lee SY, Lee KH. Recovery from Bell’s palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report. World J Clin Cases 2023; 11(12): 2817-2824 [PMID: 37214571 DOI: 10.12998/wjcc.v11.i12.2817]
Corresponding Author of This Article
Kye-Ho Lee, PhD, Stem Cell Treatment and Research Institute, bio Beauty and Health Company, 72, UN Village-gil, Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 26, 2023; 11(12): 2817-2824 Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2817
Recovery from Bell’s palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report
Hyunjun Ahn, Won-Ju Jung, Sang Yeon Lee, Kye-Ho Lee
Hyunjun Ahn, Sang Yeon Lee, Kye-Ho Lee, Stem Cell Treatment and Research Institute, bio Beauty and Health Company, Seoul 04420, South Korea
Won-Ju Jung, Stem Cell Treatment, 97.7 Beauty and Health Clinic, Seoul 04420, South Korea
Author contributions: Ahn H, Jung WJ, Lee SY and Lee KH designed the report; Ahn H and Jung WJ collected the patient’s clinical data; Ahn H and Jung WJ analyzed the data; Ahn H and Lee SY wrote the manuscript; Lee KH provided professional advice and revised the manuscript; all authors issued final approval for the version to be submitted.
Informed consent statement: The patient involved in this study gave her written informed consent authorizing disclosure of her protected health information.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest in relation to this case report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kye-Ho Lee, PhD, Stem Cell Treatment and Research Institute, bio Beauty and Health Company, 72, UN Village-gil, Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Received: December 21, 2022 Peer-review started: December 21, 2022 First decision: January 30, 2023 Revised: March 13, 2023 Accepted: March 29, 2023 Article in press: March 29, 2023 Published online: April 26, 2023 Processing time: 125 Days and 17 Hours
Abstract
BACKGROUND
Bell’s palsy is an idiopathic facial palsy with an unknown cause, and 75% of patients heal spontaneously. However, the other 25% of patients continue experiencing mild or severe disabilities, resulting in a reduced quality of life. Currently, various treatment methods have been developed to treat this disease. However, there is controversy regarding their effectiveness, and new alternative treatments are needed.
CASE SUMMARY
The patient suffered from left-sided facial paralysis due to Bell’s palsy for 7 years. The patient received an uncultured umbilical cord-derived mesenchymal stem cell transplant eight times for treatment. After follow-up for 32 mo, the paralysis was cured, and there was no recurrence.
CONCLUSION
Uncultured umbilical cord-derived mesenchymal stem cell transplantation may be a potential treatment for patients with Bell’s palsy who do not spontaneously recover.
Core Tip: The effectiveness of the current treatment methods for Bell’s palsy is debated. Therefore, alternative treatments are needed. In this study, we treated a patient with Bell’s palsy classified as moderately severe dysfunction using uncultured umbilical cord-derived mesenchymal stem cells. After follow-up for 32 mo, the paralysis was cured, and there was no recurrence. This method could be a new treatment option to replace existing treatments for Bell’s palsy.
